Menu
close
Please contact us for more information or to learn if you are eligible to participate.
The objective of the study is to determine the effectiveness of a 3rd dose and/or 4th Dose in the prevention of SARS-CoV-2 infections and determine the anti-SARS-CoV-2 IgG antibody titers using a semi quantitative 2. method at various time points (Baseline/Day0, Day14, Week12 and Week 24 after booster)
Principal Investigator | Sohail Rao, MD |
Sponsor | DHR Health Institute for Research and Development |
Type of Trial | Interventional |